Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries is a research-based international pharmaceutical company that develops high-quality, proprietary and off-patent pharmaceuticals for markets in the US, Canada, Israel and other countries. The company emphasizes research and development as key to its growth strategy.

Taro Pharmaceutical Industries

Wellness and Fitness Services

Alchemee (formerly The Proactiv Company)

Pharmaceutical Manufacturing

TARO PHARMACEUTICALS CANADA

Taro Pharmaceuticals | 39,759 followers on LinkedIn. Established in 1950, Taro Pharmaceutical Industries Ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

Avi Avramoff, R.Ph, Ph.D

Taro Pharmaceuticals

The Taro Generics team kicked off the summer with an outing to a Rockland Boulders game. The event was a fantastic opportunity for everyone to bond outside of work and strengthen our camaraderie. #TeamTaro

For over 50 years Taro Pharmaceuticals has manufactured Warfarin, a medication clinically shown to reduce the risk of death after myocardial infarction. Taro remains committed to manufacturing this and other lifesaving medications. Visit https://lnkd.in/d44_y6p5 for full prescribing information and medication guide.

Taro Pharmaceuticals is attending the National Association of Chain Drug Stores (NACDS) Annual Meeting this weekend. Stop by table 546 to meet with CEO Uday B. , VP of Generics Anthony Dolan , and VP of OTC Nivaran Kapur . We look forward to seeing you! #NACDSANNUAL #TeamTaro

On International Women’s Day, we would like to take this opportunity to reflect on the achievements and contributions of the women of Taro. Women make up 45% of our global workforce and hold nearly 50% of management level positions within the company. These numbers support Taro's aspiration to be an inclusive workplace where everyone feels valued, respected and has the opportunity to thrive. When we look at the data at a country level, the trend is similar: · In the United States, our workforce is nearly 50% women, and women hold 45% of management level positions. · In Israel, while women make up 44% of the workforce, they hold 57% of management level positions. · In Canada, 43% of our workforce are women, and they hold 46% of our management level positions. · In Japan, 61% of our workforce are women, and they hold 60% of management level positions. Additionally, women are strongly represented across our organization, even in fields that have been traditionally dominated by men. For example, globally women comprise 61% of our R&D/Regulatory/Clinical team, 66% of our Quality team, and 58% of our Supply Chain team. We are proud of the progress Taro has made in promoting gender equality and the advancement of women, and we will continue to work to ensure that Taro is a workplace where everyone has the opportunity to succeed and feels that they belong. #IWD2024 #InspireInclusion #TeamTaro

March is Blood Clot Awareness Month. Did you know that blood clots can affect anyone, anytime? This month, let's spread awareness and knowledge about the risks, signs, and preventive measures. #BCAM2024 #BCAM #TeamTaro

In recognition of American Heart Month, we were proud to partner with the Congenital Heart Defect Coalition to put together Kits of Hope for young children with heart defects who are awaiting treatment in hospitals across the country. Our Taro team members in Hawthorne, NY, assembled 100 kits that will be sent to the Children’s Hospital of Philadelphia, Children’s Hospital at Montefiore, Cohen Children’s Center, Northwell Health, Icahn School of Medicine at Mount Sinai, Boston’s Children’s Hospital and Columbia Medical Center. Thank you to our Taro volunteers for helping make a difference to these patients and their families! #TeamTaro

Taro Pharmaceuticals will be attending the National Association of Chain Drug Stores (NACDS) Annual Meeting in April. We look forward to seeing you there! #NACDSANNUAL #TeamTaro

Taro was honored to receive the Partnership in Quality Award at last week's GSMS, Incorporated annual STAR Summit. Congratulations to the team for this recognition!

Metric
Company Name	Taro Pharmaceutical Industries Ltd.
Symbol	TARO
MSH ID	COM:TARO
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	IL
Stage
Employee Count	1.55K
Website	taro.com
LinkedIn	taro-pharmaceuticals
Founders

Metric
Market Cap	1.62B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	629.18M
Revenue (LTM)
Revenue (NTM)
Gross Profit	304.98M
EBITDA	52.60M
Operating Income	21.51M
Net Income	53.87M
EPS	1.43
Diluted EPS	1.43
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.48
Operating Profit Margin	0.09
EBITDA Margin	0.08
Net Profit Margin	0.09
Return on Equity	0.03
Return on Assets	0.02
Return on Capital Employed	0.03

COM:TARO

Taro Pharmaceutical Industries

Last Close

42.97

21/06 19:59

Market Cap

1.62B

Beta: -

Volume Today

147.06K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	34.88
P/B Ratio	0.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.61
EV Multiple	55.96

Metric
Days Sales Outstanding	137.66
Days Payables Outstanding	58.83
Days Inventory Outstanding	246.91
Operating Cycle	384.57
Cash Conversion Cycle	325.74
Asset Turnover	0.29

Metric
Operating Cash Flow	132.39M
Free Cash Flow	78.17M
Cash Flow to Debt
Operating Cash Flow/Sales	0.23
Free Cash Flow Yield	0.05

Metric
Cash & Equivalents	362.91M
Accounts Receivable	40.21M
Inventory	204.82M
Goodwill	17.23M
Debt to Capitalization
Debt to Assets
Current Ratio	3.60
Quick Ratio	3.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.10
SG&A to Revenue